Chugai Pharmaceutical reports vamikibart data for Chugai Pharmaceutical stock

Published on 10/19/2026 at 10:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Chugai shared Week 52 vamikibart results on October 13, 2026. Chugai Pharmaceutical stock costs EUR 35.60 on October 19, 2026 before Q3 results.

Vamikibart data and reporting date

Chugai reported Week 52 vamikibart data on October 13, 2026.
Second-quarter 2026 revenue reached JPY 341,584 million and net income was JPY 116,331 million.
Chugai Pharmaceutical stock trades at EUR 35.60 at 10:34 a.m. CEST at Lang & Schwarz on October 19, 2026.

Chugai Pharmaceutical, JP3519400000, Illustration mit AI erstellt.

Chugai Pharmaceutical (ISIN JP3519400000) reported Week 52 vamikibart data on October 13, 2026, adding a clinical development update ahead of its next results. According to Chugai Pharmaceutical, the Phase III MEERKAT and SANDCAT studies showed sustained vision improvements and reduced macular thickness through Week 52.

Vamikibart keeps the pipeline in view

The release said two-thirds of patients entering as-needed dosing after Week 16 required no retreatment. Most patients who needed another treatment required one additional injection, while the safety profile remained consistent through Week 52. The results came from Roche's program, making the development partnership an important part of the investment case.

Chugai's second-quarter 2026 results provide the financial counterweight. Revenue reached JPY 341,584 million and net income was JPY 116,331 million, while net margin was 34.1 percent compared with 33.5 percent in the second quarter of 2025, according to Simply Wall St. The comparison shows that profit growth and margin resilience remain central to the valuation discussion.

What does the next result mean?

Chugai's next scheduled checkpoint is October 27, 2026, when it plans to publish fiscal 2026 third-quarter results for the January to September period. The investor-relations calendar also lists a results conference for October 27, 2026, according to Chugai Pharmaceutical.

Three dated signals for the stock

On April 24, 2026, Chugai's first-quarter revenue reached JPY 321.7 billion and net income was JPY 115.4 billion, as reported by Simply Wall St. On July 24, 2026, second-quarter results recorded JPY 341,584 million in revenue and JPY 116,331 million in net income. On October 13, 2026, Chugai published the Week 52 vamikibart update.

The next two dated events are the third-quarter results and the related conference, both scheduled for October 27, 2026. For investors, the key test is whether operating performance can keep pace with the value assigned to the pipeline.

Stock price and investor perspective

Chugai Pharmaceutical stock was trading at EUR 35.60 at Lang & Schwarz on October 19, 2026 at 10:34 a.m. CEST. The Tokyo Stock Exchange listing uses ticker 4519, and the company identifies the listing as Tokyo: 4519 in its vamikibart release.

The further course of trading is shown by the continuously updated real-time quote of Chugai Pharmaceutical stock.